Join our community of smart investors

Hutchmed flags fourfold increase in oncology sales

The group has two oncology drugs approved in China
Hutchmed flags fourfold increase in oncology sales
  • China-based biotech company will change its corporate nickname to ‘Hutchmed’
  • Hoping to achieve approval for third oncology drug this year

More than a quarter of the world’s cancer patients are based in China and regulatory reforms are currently under way to address major unmet medical needs in the country.

To continue reading...
OR
Register for free
Read 3 articles for free each month
Have an account? Sign in